Last updated: 3 July 2019 at 2:48am EST

John E Berriman Net Worth




The estimated Net Worth of John E Berriman is at least $648 mil dollars as of 27 May 2004. John Berriman owns over 260,000 units of Alnylam Pharmaceuticals Inc stock worth over $648,227 and over the last 20 years John sold ALNY stock worth over $0.

John Berriman ALNY stock SEC Form 4 insiders trading

John has made over 1 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently John bought 260,000 units of ALNY stock worth $1,560,000 on 27 May 2004.

The largest trade John's ever made was buying 260,000 units of Alnylam Pharmaceuticals Inc stock on 27 May 2004 worth over $1,560,000. On average, John trades about 130,000 units every 0 days since 2004. As of 27 May 2004 John still owns at least 2,475 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of John Berriman stock trades at the bottom of the page.



What's John Berriman's mailing address?

John's mailing address filed with the SEC is C/O ABINGWORTH MANAGEMENT, 38 JERMYN STREET, LONDON, , SW1Y 6DN.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, eKevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.



What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.



Complete history of John Berriman stock trades at Alnylam Pharmaceuticals Inc

Acionista maioritário
Trans.
Transação
Preço total
John E Berriman
Diretor
Comprar $1,560,000
27 May 2004


Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: